Clinical Trial Update: The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating a dendritic cell/tumor hybridoma vaccine for metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dendritic cell/tumor hybridoma vaccine (dendritic cell-tumor hybridoma vaccine)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED